GlassScriptPhysician profile
James Matthew Taylor
NPI 1952836140
$1,233.14
in general payments reported to CMS, 2019-2025
13 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2022: $360 · 2023: $370 · 2024: $181 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $411.82 | 2019-2023 | Optune |
| Boston Scientific Corporation | $326.97 | 2019-2023 | Spaceoar Vue System - 10ml |
| Janssen Biotech, INC. | $166.99 | 2022-2024 | Erleada |
| Sumitomo Pharma America, INC. | $89.27 | 2024-2025 | Orgovyx |
| Palette Life Sciences, INC. | $39.79 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $38.72 | 2025 | Libtayo |
| Daiichi Sankyo INC. | $29.60 | 2024 | Enhertu |
| Teleflex LLC | $25.82 | 2025 | Barrigel |
| Novartis Pharmaceuticals Corporation | $25.16 | 2024 | |
| Pfizer INC. | $22.42 | 2025 | |
| Pharmacosmos Therapeutics INC. | $20.47 | 2024 | Monoferric |
| Blue Earth Diagnostics | $19.96 | 2025 | Posluma |
| E.R. Squibb & Sons, L.L.C. | $16.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.